CTRI/2022/01/039380已完成未知
A Multicountry, Multicentre, Noninterventional, Retrospective Study toDescribe the Real-world Management Outcomes in Patients WithUnresectable Hepatocellular Carcinoma
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Adult female or male patients aged =18 years or ‘adults’ according to the age of majority as defined by the local regulations at index diagnosis
- •2. Patients or legal representative (unless a waiver is granted) willing and be able to provide informed consent according to local regulations. For deceased patients at study entry, informed consent is not mandatory.
- •3. Patients with radiologically or histopathologically confirmed diagnosis (at index date) of unresectable BCLC stage B HCC, not considered eligible for initial loco-regional therapya or stage C advanced or metastatic disease between 01 January 2017 and 31 December 2019.
- •4. Availability of at least 12 months of follow-up data (from the index date) in the medical records at the participating site, unless patient died within the first 12 months of diagnosis.
排除标准
- •1. Patients with BCLC stage D HCC at index diagnosis
- •2. Patients with concomitant cancer, at the time of diagnosis of unresectable HCC, except for the nonmetastatic nonmelanoma skin cancers or in situ or benign neoplasms; a cancer is considered concomitant if it occurs within 5 years of HCC diagnosis.
研究者
相似试验
已完成
不适用
Study to Describe the Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant PROstate CancerCTRI/2021/11/038126AstraZeneca Pharma India Ltd200
已完成
不适用
Multicountry Study to assess EGFR Mutations in Patients With Non-small Cell Lung CancerCTRI/2021/07/035023AstraZeneca Pharma India Limited100
已完成
不适用
Study to Determine the Treatment Patterns and Outcomes in Patients With Resectable Early-stage (IA to IIIB) Non-small Cell LungCancerCTRI/2021/11/037936AstraZeneca Pharma India Ltd200
尚未招募
不适用
A study following people with haemophilia A and B, with or without inhibitors, when on usual treatment (explorerââ??¢6)CTRI/2019/03/018292ovo Nordisk India Private Ltd
进行中（未招募）
1 期
A multicenter, international, trial to identify the molecular mechanisms of resistance and sensitivity to palbociclib re-challenge upon progression after a treatment with a palbociclib combination in metastatic breast cancer patients with positive estrogen receptorHormone receptor (HR)-positive/HER2-negative locally advanced or metastatic breast cancer (mBC). Second/third-line of endocrine treatment.MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2015-003892-31-ITMEDICA SCIENTIA INNOVATION RESEARCH S.L.33